CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Abiraterone acetate +5 moredrug
Likely dose
Abiraterone acetate 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02903160
NCT02903160Phase 2Completed
CompareCT.gov

Clinical Trial of a Rapidly Cycling, Non-Cross Reactive Regimen of Approved Therapeutic Agents to Treat Prostate Cancer

Icahn School of Medicine at Mount Sinai·interventional·Posted Sep 16, 2016·Updated Feb 7, 2024

In Brief

A Phase 2 clinical trial evaluating Abiraterone acetate, Prednisone, and 4 other interventions for Prostate Cancer. Completed, enrolled 40 participants across 2 sites.

Detailed Summary

The purpose of this study is to determine the clinical benefits of using a rapidly cycling, non-cross reactive regimen of FDA-approved prostate cancer therapeutic agents in the management of castration resistant prostate cancer. The hypothesis is that the identification of optimal combinations and sequencing of therapies can help prevent or delay the development of therapeutic drug resistance, and can be safely tolerated.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsSanofi, Bayer

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 16, 2016
Enrollment StartJan 13, 2017
Primary CompletionNov 15, 2021
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 9.8 years ago

Interventions

Abiraterone acetatedrug

Abiraterone acetate 1000 mg PO daily

Prednisonedrug

5 mg PO twice a day

Radium-223 dichloridedrug

50 kBq/kg IV monthly

cabazitaxeldrug

25 mg/m2 IV every 3 weeks

Carboplatindrug

Carboplatin AUC 4 IV every 3 weeks

Enzalutamidedrug

160 mg PO daily